Q1 2026 Agios Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Agios Pharmaceuticals Inc (AGIO) reported $20.7 million in net revenues for the first quarter, marking a 138% growth year-over-year.
- The US commercial launch of AQVESME in thalassemia is off to a strong start with 242 prescriptions written by REMS-certified physicians by March 31.
- Agios Pharmaceuticals Inc (AGIO) ended the quarter with a strong balance sheet, including over $1 billion in cash, cash equivalents, and marketable securities.
- The company plans to submit an sNDA for mitapivat in sickle cell disease in the second quarter under the US accelerated approval pathway.
- Agios Pharmaceuticals Inc (AGIO) is preparing for important mid-term catalysts, including Phase II top line data for tebapivat in both lower-risk MDS and sickle cell disease this year.
- Operating expenses are expected to remain approximately flat compared to 2025, indicating limited cost reduction efforts.
- There is expected variability in quarterly revenues outside the US due to early market access dynamics and government procurement processes.
- The time from prescription to initiation for AQVESME is expected to average 10 to 12 weeks, which may delay revenue realization.
- The company faces competition in the sickle cell disease market, which could impact the commercial opportunity for mitapivat.
- Agios Pharmaceuticals Inc (AGIO) reported increased R&D and SG&A expenses, driven by workforce-related costs and stock compensation, which could pressure margins.
Good day, and thank you for standing by. Welcome to the first quarter 2026 Agios financial results and business highlights. (Operator Instructions) Please be advised that today's call is being recorded.
I would now like to hand it over to our first speaker, Morgan Sanford, Head of Investor Relations at Agios. Please go ahead.
Thank you, operator. Good morning, everyone. Thank you for joining us to discuss Agios Pharmaceuticals first quarter 2026 financial results and business highlights. You can access the slides for today's call by going to the Investors section of our website, agios.com.
Please note, we'll be making certain forward-looking statements today. Actual events and results could differ materially from those expressed or implied by any forward-looking statements because of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC.
On the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
